ANG Lifesciences India Limited (ANGL) is a pharmaceutical company based in Amritsar, Punjab. It was incorporated in 2006. ANG Lifesciences India Limited is coming up with a fixed price IPO shortly. ANG Lifesciences IPO review will delve into the draft prospectus and present a critical review of this IPO.
About the Issue – ANG Lifesciences India Ltd IPO review finds the following details of the issue as per draft prospectus submitted to BSE.
- Issue opens on – 29 August 2017
- Issue closes on – 31 August 2017
- Issue type – Fixed price issue IPO
- Issue price – Rs 80 per equity share
- Lot size – A minimum quantity of 1600 shares and in multiples thereof
- Face value – Rs 10 per equity share
- Issue size – 1,500,800 nos. of equity shares aggregating up to Rs 12.01 crores
- Listing Exchange – BSE SME exchange
Objects of the issue – The proceeds from this IPO will be used to – a) to meet issue expenses, b) to meet general corporate expenses and c) to fulfill the demand for working capital.
About the company – ANG Lifesciences India Limited (ANGL) is a Punjab based pharmaceutical company engaged in the business of manufacturing and marketing of different pharmaceutical formulations in finished form as the dosage form of sterile dry powder vials for injection in the Indian market.
ANG Lifesciences India Limited manufactures and markets dry powder vials for antibiotics, anti malarial, anti inflammatory, anti ulcer, glucocorticoid and anesthetic drugs in compliance with GMP guideline. The company is also on the lookout for acquisition to increase its business. Also, in the last two fiscals, the company is only using 70% of its capacity utilization and ANGL has set the target to take capacity utilization to 90% by the next two fiscals. Big pharma companies like Wockhardt, Global Hospitals, DHS Maharashtra, Elder, BPPI, Emcure, Govt. of Haryana, Hetero Healthcare and the likes are regular clients of ANGL.
Company Financials –
Since it’s incorporation, ANGL is doing good business in the last few fiscals as per the restated financial statement. But ANG Lifesciences India Ltd IPO review finds PAT shows fluctuating growth rate. The company is a relatively small company and has long-term and short-term debts.
Conclusion – ANG Lifesciences IPO review has NEUTRAL views on this issue. An investor, though, may follow our articles on last day IPO investment techniques for investment ideas.
Disclaimer – Views expressed in this review is an educated guess made on the basis of available data from open source expressed for the purpose of knowledge sharing. By no means, it should be taken as an investment advice or recommendation. Investor/ trader should invest money at their own risk.